429 related articles for article (PubMed ID: 37686080)
41. Post-translational modification of lysine residues in erythrocyte α-synuclein.
Amagai R; Yoshioka S; Otomo R; Nagano H; Hashimoto N; Sakakibara R; Tanaka T; Okado-Matsumoto A
J Biochem; 2023 Mar; 173(3):177-184. PubMed ID: 36469357
[TBL] [Abstract][Full Text] [Related]
42. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
[TBL] [Abstract][Full Text] [Related]
43. Effect of Disease-Associated P123H and V70M Mutations on β-Synuclein Fibrillation.
Sharma K; Mehra S; Sawner AS; Markam PS; Panigrahi R; Navalkar A; Chatterjee D; Kumar R; Kadu P; Patel K; Ray S; Kumar A; Maji SK
ACS Chem Neurosci; 2020 Sep; 11(18):2836-2848. PubMed ID: 32833434
[TBL] [Abstract][Full Text] [Related]
44. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
Knecht L; Folke J; Dodel R; Ross JA; Albus A
Neurotherapeutics; 2022 Sep; 19(5):1489-1502. PubMed ID: 36083395
[TBL] [Abstract][Full Text] [Related]
45. The 3D structure of lipidic fibrils of α-synuclein.
Frieg B; Antonschmidt L; Dienemann C; Geraets JA; Najbauer EE; Matthes D; de Groot BL; Andreas LB; Becker S; Griesinger C; Schröder GF
Nat Commun; 2022 Nov; 13(1):6810. PubMed ID: 36357403
[TBL] [Abstract][Full Text] [Related]
46. Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies.
Sandoval IM; Marmion DJ; Meyers KT; Manfredsson FP
J Parkinsons Dis; 2021; 11(s2):S189-S197. PubMed ID: 34092656
[TBL] [Abstract][Full Text] [Related]
47. Tau accelerates α-synuclein aggregation and spreading in Parkinson's disease.
Pan L; Li C; Meng L; Tian Y; He M; Yuan X; Zhang G; Zhang Z; Xiong J; Chen G; Zhang Z
Brain; 2022 Oct; 145(10):3454-3471. PubMed ID: 35552614
[TBL] [Abstract][Full Text] [Related]
48. Novel naturally occurring autoantibodies attenuate α-synuclein pathology in a mouse model of Parkinson's disease.
Li Y; Wang T; Meng L; Jin L; Liu C; Liang Y; Ren L; Liu Y; Liu Y; Liu S; Li T; Liang Y; Chen X; Zhang Z
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12860. PubMed ID: 36331758
[TBL] [Abstract][Full Text] [Related]
49. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
50. α-Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline.
Chu WT; DeSimone JC; Riffe CJ; Liu H; Chakrabarty P; Giasson BI; Vedam-Mai V; Vaillancourt DE
J Neurosci; 2020 Aug; 40(34):6649-6659. PubMed ID: 32669353
[No Abstract] [Full Text] [Related]
51. alpha-Synuclein membrane interactions and lipid specificity.
Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE
J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790
[TBL] [Abstract][Full Text] [Related]
52. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
53. Revisiting the role of 3-nitrotyrosine residues in the formation of alpha-synuclein oligomers and fibrils.
Chavarría C; Ivagnes R; Zeida A; Piñeyro MD; Souza JM
Arch Biochem Biophys; 2024 Feb; 752():109858. PubMed ID: 38104957
[TBL] [Abstract][Full Text] [Related]
54. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis.
Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK
J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838
[TBL] [Abstract][Full Text] [Related]
55. Nitroalkylation of α-Synuclein by Nitro-Oleic Acid: Implications for Parkinson's Disease.
Chavarría C; Trostchansky A; Durán R; Rubbo H; Souza JM
Adv Exp Med Biol; 2019; 1127():169-179. PubMed ID: 31140178
[TBL] [Abstract][Full Text] [Related]
56. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
57. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
58. Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.
Duce JA; Wong BX; Durham H; Devedjian JC; Smith DP; Devos D
Mol Neurodegener; 2017 Jun; 12(1):45. PubMed ID: 28592304
[TBL] [Abstract][Full Text] [Related]
59. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
60. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
